VAXDIAX

The rapid test for the detection of antibodies after COVID-19 vaccinations

The VAXDIAX antibody test is an in-vitro diagnostic rapid test for the qualitative detection of highly specific neutralising antibodies against SARS-CoV-2 after COVID-19 vaccination.

 

The test, developed, produced and CE-certified in Germany, is set to an analytical sensitivity of 35 BAU/ml. Depending on the titre strength, the VAXDIAX test indicates the status of protective antibodies in just 10 minutes according to the WHO International Standard for anti-SARS-COV-2-immunoglobulin.